Daridorexant for insomnia disorder

Abstract

Insomnia disorder is defined by difficulties initiating or maintaining sleep, or both, resulting in substantial daytime dysfunction. 1 Morin CM Drake CL Harvey AG et al. Insomnia disorder. Nat Rev Dis Primers. 2015; 115026 Google Scholar In industrialised countries, 5–10% of the general population have the disorder. 2 Ohayon MM Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002; 6: 97-111 Google Scholar According to the guidelines of the American College of Physicians 3 Qaseem A Kansagara D Forciea MA Cooke M Denberg TD Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016; 165: 125-133 Google Scholar and the European Sleep Research Society, 4 Riemann D Baglioni C Bassetti C et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017; 26: 675-700 Google Scholar the first-line treatment for the disorder is cognitive behavioural therapy for insomnia (CBT-I). This treatment is safe and effective but not widely available. 1 Morin CM Drake CL Harvey AG et al. Insomnia disorder. Nat Rev Dis Primers. 2015; 115026 Google Scholar Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsDaridorexant 25 mg and 50 mg improved sleep outcomes, and daridorexant 50 mg also improved daytime functioning, in people with insomnia disorder, with a favourable safety profile. Full-Text PDF